Tag: cannabidiolCBD

Studies

• Mixed Effects and Mechanisms of Cannabinoids for Triple-Negative Breast Cancer Treatment Cite
  Tran K. Mixed Effects and Mechanisms of Cannabinoids for Triple-Negative Breast Cancer Treatment. MDPI AG; 2021; 10.20944/preprints202107.0614.v1
• Cannabidiol Loaded Extracellular Vesicles Sensitize Triple-Negative Breast Cancer to Doxorubicin in both in-vitro and in vivo Models Running Title: Formulation and anti-cancer potential of CBD loaded hUCMSC-derived Extracellular Vesicles in TNBC Cite
  Patel N, Kommineni N, Kumar Surapaneni S, Kalvala A, Yaun X, Gebeyehu A, et al. Cannabidiol Loaded Extracellular Vesicles Sensitize Triple-Negative Breast Cancer to Doxorubicin in both in-vitro and in vivo Models Running Title: Formulation and anti-cancer potential of CBD loaded hUCMSC-derived Extracellular Vesicles in TNBC. International Journal of Pharmaceutics. Elsevier BV; 2021;:120943 10.1016/j.ijpharm.2021.120943
• Two Worlds Colliding: The Interplay Between Natural Compounds and Non-Coding Transcripts in Cancer Therapy Cite
  Sabo AA, Dudau M, Constantin GL, Pop TC, Geilfus C, Naccarati A, et al. Two Worlds Colliding: The Interplay Between Natural Compounds and Non-Coding Transcripts in Cancer Therapy. Frontiers in Pharmacology. Frontiers Media SA; 2021; 12 10.3389/fphar.2021.652074
• Cannabinoids and Child Development: During and After Pregnancy Cite
  Chen QC, Narouze SN. Cannabinoids and Child Development: During and After Pregnancy. Cannabinoids and Pain. Springer International Publishing; 2021;:287-290 10.1007/978-3-030-69186-8_35
• Reduction in Tamoxifen Metabolites Endoxifen and N-desmethyltamoxifen With Chronic Administration of Low Dose Cannabidiol: A CYP3A4 and CYP2D6 Drug Interaction Cite
  Parihar V, Rogers A, Blain AM, Zacharias SRK, Patterson LL, Siyam MA. Reduction in Tamoxifen Metabolites Endoxifen and N-desmethyltamoxifen With Chronic Administration of Low Dose Cannabidiol: A CYP3A4 and CYP2D6 Drug Interaction. Journal of Pharmacy Practice. SAGE Publications; 2020;:089719002097220 10.1177/0897190020972208
• Cannabidiol (CBD) as a Promising Anti-Cancer Drug Cite
  Seltzer ES, Watters AK, MacKenzie D, Granat LM, Zhang D. Cannabidiol (CBD) as a Promising Anti-Cancer Drug. Cancers. MDPI AG; 2020; 12:3203 10.3390/cancers12113203
• Abstract P3-05-11: Cannabidiol increases potency of tamoxifen in inhibiting breast cancer cell viability Cite
  Dobovišek L, Novak M, Krstanović F, Ferk P, Borštnar S, Turnšek TL, et al. Abstract P3-05-11: Cannabidiol increases potency of tamoxifen in inhibiting breast cancer cell viability. Poster Session Abstracts. American Association for Cancer Research; 2020; 10.1158/1538-7445.sabcs19-p3-05-11
• Estrogenic effects of marijuana smoke condensate and cannabinoid compounds Cite
  Lee SY, Oh SM, Chung KH. Estrogenic effects of marijuana smoke condensate and cannabinoid compounds. Toxicology and Applied Pharmacology. Elsevier BV; 2006; 214:270-278 10.1016/j.taap.2005.12.019
• Cannabinoids for Symptom Management and Cancer Therapy: The Evidence Cite
  Davis MP. Cannabinoids for Symptom Management and Cancer Therapy: The Evidence. Journal of the National Comprehensive Cancer Network. Harborside Press, LLC; 2016; 14:915-922 10.6004/jnccn.2016.0094
• Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain Cite
  Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain. Journal of Pain and Symptom Management. Elsevier BV; 2010; 39:167-179 10.1016/j.jpainsymman.2009.06.008
• Failure of cannabinoid compounds to stimulate estrogen receptors Cite
  Ruh MF, Taylor JA, Howlett AC, Welshons WV. Failure of cannabinoid compounds to stimulate estrogen receptors. Biochemical Pharmacology. Elsevier BV; 1997; 53:35-41 10.1016/s0006-2952(96)00659-4